CT0180

CT0180 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy being developed by CARsgen Therapeutics in collaboration with Zhejiang University for the treatment of advanced hepatocellular carcinoma (HCC). The therapy consists of a patient's own T cells engineered to express a chimeric antigen receptor (CAR) that specifically targets glypican-3 (GPC3), a cell-surface oncofetal antigen overexpressed in the majority of HCC cases but with limited expression in normal adult tissues. By binding to GPC3, the engineered T cells are directed to recognize and eliminate GPC3-positive tumor cells. CT0180 is currently undergoing Phase I clinical evaluation to assess its safety, tolerability, and pharmacokinetics in patients with GPC3-positive advanced HCC.

Other names

anti-GPC3 CAR-Tanti-GPC-3 CAR-Tanti-GPC 3 CAR-Tchimeric anti-GPC3 scFv-CD3ε engineered T cellsCT0180 CellsCT-0180 CellsCT 0180 CellsCT0180 InjectionCT-0180 InjectionCT 0180 Injection